RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Legend Biotech of Nanjing, a GenScript Biotech subsidiary, reported FDA approval of a US Phase Ib/II trial for its CAR-T therapy in patients with relapsed or refractory multiple myeloma. One year ago, Legend stunned the ASCO cancer convention with a very positive 94% response rate from a China trial of the CAR-T candidate. In December 2017, Janssen paid Legend a record $350 million upfront for a global partnership to develop the immunotherapy. Janssen and Legend plan to begin enrollment of the US trial in the second half of 2018.
Source: China Biotoday
